全球血吸蟲病藥物市場2022-2029
市場調查報告書
商品編碼
1140669

全球血吸蟲病藥物市場2022-2029

Global Schistosomiasis Drugs Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

2021 年血吸蟲病藥物市場價值 7040 萬美元。預計在預測期內(2022-2029 年)將以 3.8% 的複合年增長率增長。

血吸蟲病,又稱吸血吸蟲、血吸蟲、片山熱,是由寄生蟲血吸蟲引起的急慢性疾病。該病通過水傳播感染傳播。血吸蟲寄生蟲生活在河流、湖泊、水上公園、池塘、水池、市政水域和溪流中。感染血吸蟲、曼氏血吸蟲和日本血吸蟲會導致人類疾病,但鮮為人知的湄公河沙門氏菌和插間沙門氏菌也會引起疾病。然而,儘管在美國尚未發現導致血吸蟲病的蠕蟲,但它感染了全球超過 2 億人。感染通過直接接觸受感染的動物或人而傳播。 2018年,78個國家報告了血吸蟲病病例。

血吸蟲病的症狀是由身體對蟲卵的反應引起的。症狀包括腹部絞痛、腹瀉、便血、尿血、嘔吐、肝臟腫大、發燒、腎臟損傷、虛弱、皮疹和身體疼痛。其他慢性症狀包括生殖器病變、陰道出血和外陰結節。建議由醫療保健專業人員重複測試以檢查糞便和尿液中的血吸蟲病。聚合□鏈反應 (PCR) 測試和血液測試也可以幫助診斷血吸蟲病。如果尿液或糞便中沒有發現卵子,建議進行其他檢查,例如內窺鏡檢查、結腸鏡檢查、超聲、肝活檢和 MRI,以獲得更好的診斷。如果不及時治療,偏頭痛會導致並發症,如心肺、胃腸道、中樞神經系統、脾臟、肝臟、細菌感染、尿瀦留,甚至死亡。

市場動態

全球血吸蟲病藥物市場的增長是由血吸蟲病患病率上升、醫療保健設施不足以及發展中國家缺乏安全飲用水等因素推動的。

血吸蟲病患病率上升正在推動市場增長

超過 1.4 億人(其中 90% 生活在非洲)感染了血吸蟲病。在該疾病流行的 76 個國家,估計有 7 億人因農業、家庭和娛樂活動接觸受感染的水而面臨感染風險。全世界每年有 200,000 人死於血吸蟲病。一些國家的感染已經停止。據世界衛生組織(WHO)估計,2019 年約有 2.366 億人需要血吸蟲病預防性治療,其中超過 1.054 億人據報導接受了治療。

因此,血吸蟲病的日益流行刺激了私人製造商和研究機構對其治療的研究和開發。幾項臨床試驗正在進行中,以擴大血吸蟲病藥物的潛力。

用於治療血吸蟲病的新型疫苗的不斷開發有望推動市場增長

2021 年 6 月 1 日,國際疫苗研究所 (IVI) 授予比爾和梅琳達·蓋茨基金會的贈款,用於設計和開發適用於偏頭痛疫苗 Ib/IIa 期臨床試驗的方案。這種疫苗提供了一種具有成本效益和安全的疫苗。幾種疫苗正在開發中,正在申請專利的疫苗也已在中國、印度和巴西申請。新疫苗開發旨在開發這種疫苗並以可承受的價格將其分發給受感染的人。預計這一發展將在預測期內推動血吸蟲病藥物市場的增長。

對血吸蟲病預防的高需求推動了血吸蟲病藥物市場

根據世界衛生組織 (WHO) 2018 年的數據,超過 78 個國家長期感染血吸蟲病,其中 52 人需要預防性化療。世衛組織估計,2018 年將有約 2.292 億人需要預防性化療,其中約 1.244 億為學齡兒童。

然而,該藥物的高成本和嚴格的審批程序正在抑制市場增長。龐大的患者群體和未滿足的醫療需求預計將為市場增長提供有利可圖的機會。

流行病學

急性和慢性血吸蟲感染在美國並不常見。然而,隨著估計有 400,000 名感染者遷移到美國,沒有足夠大的易感蝸牛物種或慢性感染者進入淡水的水庫。致病性偏頭痛可以在人類宿主中長期存活和復制。因此,旅行或移民的人可能會因急性或慢性血吸蟲病和相關的終末器官並發症的活躍病例而到急診室就診。許多感染者仍然沒有症狀。由於暴露後會產生強烈的免疫反應,因此急性症狀在未接種疫苗的旅行者中更為常見。

在全球範圍內(不包括美國),血吸蟲病是導致死亡和發病的主要原因。由曼氏血吸蟲引起的腸道血吸蟲病在加勒比國家(即波多黎各、聖盧西亞、蒙特塞拉特、安提瓜、馬提尼克、瓜德羅普、多米尼加共和國)、東地中海國家、南美國家(即巴西、委內瑞拉、蘇裡南)很常見。大約 52 個國家,包括非洲的大部分地區。

S intercalatum 分佈於中非熱帶雨林內的大約 10 個國家。日本血吸蟲在西太平洋地區的四個國家(中國、印度尼西亞、菲律賓和泰國)流行。 S mekongi 是東南亞湄公河流域(柬埔寨、老撾、泰國)的地方病。血吸蟲尿路血吸蟲病感染了非洲和東地中海的 54 個國家。

大約 74 個國家的超過 2.07 億人感染了血吸蟲病。其中,約 60% 有疾病症狀,例如因感染引起的器官特異性主訴以及與慢性貧血和營養不良有關的問題,超過 2000 萬人處於危急狀態。

但是,在中國、巴西、埃及和撒哈拉以南非洲部分地區等不同的流行地區,結合了蝸牛控制、水質改善和感染者(尤其是兒童)治療的重點干預措施已被證明是有效的。已經成功

根據世衛組織的公告,血吸蟲病的全球分佈正在發生變化。它已在日本和小安的列斯群島被根除,在突尼斯停止,在沙特阿拉伯、摩洛哥、委內瑞拉和波多黎各非常低。

市場細分。

血吸蟲病藥物市場可以根據地點、品種類型、藥物類別和分銷渠道進行細分。

按藥物類型來看,□奎酮(Virticide)有望快速增長

□奎酮(殺蟲劑)。□奎酮用於治療血吸蟲病,對成蟲更有效。□奎酮用於治療個體患者和大型社區治療項目。這種藥物的作用機制很複雜,會引起超微結構變化並增加對鈣離子的滲透性。鈣離子在寄生蟲的細胞質內積聚,導致成蟲肌肉收縮並最終癱瘓。線蟲的外膜受損,線蟲暴露於患者的免疫反應中,導致線蟲死亡。□奎酮的回收率超過85%。在那些沒有恢復的人中,卵子負擔顯著減少。

奧沙尼奎(Vansil)。 Oxamniquin 僅對 S mansoni 有效。這種藥物的治愈率約為60-90%。 Oxamniquin 在美國不再可用。奧沙尼奎被偏頭痛細菌代謝為酯類。這種藥物會破壞雄性半寄生蟲的外層皮膚,從而使患者的免疫系統能夠殺死該生物體。它還可以阻止雌性寄生蟲產卵。手術選擇包括腫瘤切除、分流手術和肉芽腫切除。其作用機制複雜。

大多數人類血吸蟲病是由血吸蟲、曼氏血吸蟲和日本血吸蟲引起的。不太常見的物種,如 S mekongi 和 S intercalatum 也可引起系統性人類疾病。其他以禽類或哺乳動物為宿主的血吸蟲也可導致人類嚴重的皮炎(例如 Trichobilharzia ocellata)。

地理特徵

中東和非洲主導著全球血吸蟲病藥物市場。

中東和非洲地區在血吸蟲病藥物市場的份額最大,其次是南美、亞洲、歐洲和北美。南非是中東和非洲地區血吸蟲病市場的最大貢獻者。在南美,由於患者人數的增加,市場正在迅速擴大,主要是在巴西。然而,預計歐洲和亞太地區在預測期內將增長。大約有 1.2 億人出現血吸蟲病症狀,其中 2000 萬人患有嚴重的臨床疾病。在撒哈拉以南非洲,每年有超過 20 萬人死於血吸蟲病。用受感染的水洗衣服的婦女風險很大。衛生和玩泥和水會使兒童更容易受到感染。大約有 4000 萬育齡婦女受到感染。非洲約有 1000 萬婦女在懷孕期間患有血吸蟲病。

在非洲和巴西,難民流向城市地區導致了新的感染地區。由於人口增長和對電力和水的需求增加,感染正在蔓延。大約 5-10% 的流行地區受到嚴重感染,其餘為輕度至中度感染。居住在河流和湖泊附近的人感染的風險最高。在烏干達,在海拔 1400 米或以上且年降雨量小於 900 毫米的地方幾乎沒有確診感染。

在西太平洋地區,日本血吸蟲腸造口術在菲律賓和中國流行,湄公血吸蟲在柬埔寨兩省和老撾人民民主共和國一省流行。腸道寄生蟲引起腹痛、腹瀉和血便。根除該地區的血吸蟲病將通過包括健康促進、預防性化療運動、水和環境衛生 (WASH) 改善、牲畜治療和管理以及局部蝸牛控制在內的單一健康方法來加強社區。

競爭格局

血吸蟲病市場的主要參與者包括 Chemos GmbH &Co.KG、Shin Poong Pharma.Co.Ltd.、Meher Distributors Pvt. Ltd.、Merck &Co.、Salvensis、Bayer AG、LondonPharma Ltd、Merck &Co., Inc., 3S Corporation Kancera AB, Taj Pharmaceuticals Ltd., Avanscure Lifesciences Pvt. Ltd., CBC Pharma., VHB Life Science Inc., Samarth Pharma Pvt. Ltd., Taj Pharmaceuticals Ltd. 和埃及國際製藥工業公司 SAE (EIPICO)。這些公司提供多種用於預防性化療的藥物。主要參與者採用了多種增長戰略,例如產品發布、收購和合作夥伴關係,這些戰略為偏頭痛藥物市場的全球增長做出了貢獻。

2019 年 3 月,IDDO 與熱帶病研究和培訓特別計劃 (TDR) 發起了一項新的全球科學合作,專門針對偏頭痛和 STH。它旨在擴大數據重用和協作,以加速更好地治療和管理這些影響全球超過 10 億人的疾病。

2020 年 1 月,科技領導者默克公司向世界衛生組織 (WHO) 捐贈了 10 億片□奎酮片,這是治療血吸蟲病的護理標準。這是結束主要影響貧困農村地區兒童的被忽視熱帶病 (NTD) 的重要裡程碑。自 2007 年以來,我們的□奎酮已使撒哈拉以南非洲地區 4 億學齡兒童得到治療。

拜耳 K.K.

概述

拜耳公司是一家德國跨國製藥和生命科學公司,總部位於勒沃庫森。拜耳的業務領域包括人用和獸用藥物、消費者保健產品、農用化學品、種子和生物技術產品。製藥部門專注於處方藥,尤其是女性保健和心血管醫學,以及腫瘤學、血液學和眼科領域的特殊藥物。我們還有一個放射學業務部門,銷售帶有造影劑和造影劑的診斷成像系統。

產品組合

BILTRICIDE(□奎酮)。□奎酮是一種用於治療寄生蟲感染的藥物。具體而言,它用於血吸蟲病、絨毛蟲病、後睪症、絛蟲感染、囊尾蚴病、包蟲病和其他流感感染。不用於寄生蟲眼部感染。口服給藥。

COVID-19 影響分析

COVID-19 正在通過對生產和需求的直接影響、供應鏈中斷和市場中斷以及對企業和金融市場的財務影響來影響全球經濟。由於 COVID-19 大流行,全球偏頭痛藥物市場呈現負增長。這是因為越來越多的利益相關者呼籲採用新的方法來診斷和治療受 COVID-19 影響的患者。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按產品劃分的市場細分
  • 按產品類型劃分的市場細分
  • 按藥物類型劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
  • 驅動程序
    • 血吸蟲病發病率上升
  • 限制因素
    • 嚴格的監管審批
  • 商機
  • 影響分析

第5章行業分析

  • 波特五力分析
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按部分

  • 腸交界處血吸蟲病
  • 泌尿生殖系統血吸蟲病

第 8 章按物種分類

  • 曼氏原蟲
  • 日本血吸蟲
  • 湄公血吸蟲
  • 幾內亞血吸蟲
  • 血吸蟲

第 9 章按藥物類型

  • □奎酮(殺病毒劑)
  • 奧沙尼金(Bancil)
  • 甲磺酸
  • 其他

第 10 章按銷售渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 13 章公司簡介

  • 拜耳公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Merck & Co., Inc.
  • Avanscure Lifesciences Pvt. Ltd.
  • Shin Poong Pharma.Co., Ltd.
  • Egyptian International Pharmaceuticals Industries Co SAE(EIPICO)
  • CBC Pharma.
  • Chemos GmbH & Co. KG.
  • VHB Life Science Inc.
  • 3S Corporation Kancera AB
  • Taj Pharmaceuticals Ltd.(List Not Exhaustive)

第14章 DataM

簡介目錄
Product Code: DMPH2738

Market Overview

Schistosomiasis Drugs market was valued at USD 70.4 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 3.8% during the forecast period (2022-2029).

Schistosomiasis, also known as Bilharzia, blood fluke, and Katayama fever, is an acute and chronic disease caused by the parasitic worm Schistosoma genus. The disease is spread through waterborne transmission. The Schistosoma parasites are found in rivers, lakes, water parks, ponds, swimming pools, municipal water, and streams. Infection with S. haematobium, Schistosoma mansoni, and S. japonicum causes illness in humans while less commonly, S. mekongi and S. intercalatum can cause disease. However, the worms that cause schistosomiasis are not found in the United States, but more than 200 million people are infected worldwide. Infection can be spread through direct contact with the infected animal and person. In 2018, schistosomiasis transmission had been reported from 78 countries.

Schistosomiasis symptoms occur when the body reacts to the worms' eggs. Abdominal cramps, diarrhea, blood in the stool, blood in urine, vomiting, liver enlargement, fever, kidney damage, weakness, rash, and body aches are some of the symptoms of the disease. Some other chronic symptoms include genital lesions, vaginal bleeding, and nodules in the vulva. It is recommended by healthcare professionals for repeated examination to confirm the schistosomiasis parasite in the stool and urine. Polymerase chain reaction (PCR) tests and blood tests also help to diagnose schistosomiasis. If no eggs are found in urine or feces other tests such as endoscopy, colonoscopy, echocardiograms, ultrasound, liver biopsy, and MRI, are recommended for better diagnosis. If schistosomiasis is left untreated, it may lead to complications related to the cardiopulmonary, gastrointestinal, central nervous system, spleen, liver, bacterial infections, urinary obstruction, and even death.

Market Dynamics

The global schistosomiasis drugs market growth is driven by factors such as the rising prevalence of schistosomiasis, inadequate healthcare facilities, and lack of safe drinking water in developing countries.

The increasing incidence of Schistosomiasis is driving the market growth

More than 140 million people, 90% of who live in Africa, are infected with schistosomiasis. An estimated 700 million people are at risk of infection in 76 countries where the disease is considered endemic, as their agricultural work, domestic chores, and recreational activities expose them to infested water. Globally, 200,000 deaths are attributed to schistosomiasis annually. Transmission is interrupted in some countries. The World Health Organization (WHO) estimates show that in 2019, about 236.6 million people required preventive treatment for schistosomiasis, out of which more than 105.4 million people were reported to have been treated in 2019.

Hence, the increasing incidence of schistosomiasis is leading to a rise in research and development for its treatment by private manufacturers and research organizations. Several clinical trials are undergoing to expand the potential future of schistosomiasis drugs.

The growing development of novel vaccines for the treatment of schistosomiasis is expected to drive the market growth

On 1st June 2021, The International Vaccine Institute (IVI) received a grant from the Bill & Melinda Gates Foundation to design and develop the adaptive protocol for the phase of Ib/IIa clinical trials for the schistosomiasis vaccine. The vaccine offers in cost-effective and safe. Some vaccines are under development, and some vaccines in patent applications have also been filed in China, India, and Brazil. The development of new vaccines aims to develop and distribute this vaccine at affordable rates for infected people. This development is expected to drive the growth of the schistosomiasis drugs market over the forecast period.

High demand for preventive chemotherapy against schistosomiasis is boosting the schistosomiasis drugs market

As per the World Health Organization (WHO) in 2018, more than 78 countries are constantly infected for schistosomiasis, in which population of 52 countries require preventive chemotherapy. In addition, according to the WHO estimates, in 2018, around 229.2 million people required preventive chemotherapy; among them, around 124.4 million were school-aged children.

However, the high cost of drugs and stringent approval process restrains the market growth. The presence of a large patient pool and unmet medical needs are anticipated to provide lucrative opportunities for market growth.

Epidemiology

In the United States, acute and chronic schistosomiasis infections are not common. However, it is estimated that around 400,000 infected persons have immigrated to the U.S., neither susceptible snail species nor chronically infected human reservoirs sufficient to infest freshwater exists. Pathogenic schistosomes can survive and replicate in human hosts for a long time. Hence, persons who have traveled or immigrated may present to EDs with active cases of acute or chronic schistosomiasis and associated end-organ complications. Most of the infected patients remain asymptomatic. Acute symptoms are more common in nonimmune travelers because of a severe immune response following exposure.

Globally (excluding the United States), schistosomiasis is a major source of mortality and morbidity. Intestinal schistosomiasis caused by S mansoni occurs in about 52 nations, including Caribbean countries (i.e., Puerto Rico, Saint Lucia, Montserrat, Antigua, Martinique, Guadeloupe, Dominican Republic), eastern Mediterranean countries, South American countries (i.e., Brazil, Venezuela, Surinam), and most countries in Africa.

Other Schistosoma species that may cause intestinal symptoms and diseases include S japonicum, S intercalatum, and S mekongi.S intercalatum is found in about ten countries within the rain forests of Central Africa. S japonicum is endemic in 4 countries in the western Pacific region (i.e., China, Indonesia, Philippines, Thailand). S mekongi infection occurs in the Mekong River area of Southeast Asia (i.e., Kampuchea, Laos, Thailand). The urinary schistosomiasis caused by S haematobium affects 54 countries in Africa and the eastern Mediterranean.

Over 207 million people in around 74 countries have the active schistosomal infection. Of this population, around 60% have disease symptoms, including organ-specific complaints and problems related to chronic anemia and malnutrition from the infection; more than 20 million are severely ill.

However, the targeted interventions combining snail control improved water supply quality, and treatment of infected persons, especially children, have shown success in diverse endemic areas, including China, Brazil, Egypt, and some areas of sub-Saharan Africa.

As per the WHO, the global distribution of schistosomiasis has changed. It has been eradicated from Japan and Lesser Antilles islands, the transmission has been stopped in Tunisia, and the transmission is very low in Saudi Arabia, Morocco, Venezuela, and Puerto Rico.

Market Segmentation:

The schistosomiasis drugs market can be segmented based on-site, species type, drug class, and distribution channel.

By Drugs type, Praziquantel (Biltricide) is expected to witness rapid growth

Praziquantel (Biltricide): Praziquantel drug is used to treat schistosomiasis and is more effective on adult worms. Praziquantel is used for the treatment of individual patients and mass community treatment programs. The mechanism of action is complex for this drug as it induces ultrastructural changes resulting in increased permeability to calcium ions. Calcium ions accumulate in the parasite cytosol, which leads to muscle contractions and ultimate paralysis of adult worms. The tegument membrane of the worm is damaged, exposing the worm to the immune response of the patient, which leads to worm death. The recovery rate with praziquantel is more than 85%. In persons not recovered, the egg burden is markedly decreased.

Oxamniquine (Vansil): Oxamniquine is effective only against S mansoni. The cure rate with the drug is around 60-90%. Oxamniquine is no longer available in the United States. Oxamniquine drug is metabolized into an ester by schistosomes. The drug damages the tegument of male schistosome worms so that the immune system of the patient can kill the organisms. It stops female worms from producing eggs. Surgical alternatives can include the removal of tumors, shunt surgeries, and granuloma removal. Its mechanism of action is complex.

Most human schistosomiasis is caused by S haematobium, S mansoni, and S japonicum. Less prevalent species, such as S mekongi and S intercalatum, may also cause systemic human disease. Less importantly, other schistosomes with avian or mammalian primary hosts can cause severe dermatitis in humans (e.g., swimmer's itch secondary to Trichobilharzia ocellata).

Geographical Presentation

The Middle East & Africa is dominating the global schistosomiasis drugs market

The Middle East & Africa region accounted for the largest share of the schistosomiasis drugs market, followed by South America, Asia, Europe, and North America. South Africa is the largest contributor to the schistosomiasis drugs market in Middle East & Africa. The market in South America is expanding rapidly due to an increase in the patient population, especially in Brazil. However, Europe and Asia-Pacific are estimated to grow over the forecast period. Around 120 million people are symptomatic with schistosomiasis, with 20 million having severe clinical disease. Over 200,000 deaths per year are due to schistosomiasis in sub-Saharan Africa. Women washing clothes in infested water are at major risk. Hygiene and playing in mud and water make children vulnerable to infection. Around forty million women of childbearing age are infected. Around 10 million women in Africa have schistosomiasis during pregnancy.

In Africa and Brazil, refugee migration to urban areas is transmitting the disease to new locations. Rising population size and growing needs for power and water have led to increasing transmission. Around 5-10% of an endemic community are heavily infected, and the remainder has mild to moderate infections. The risk of infection is highest amongst those who lived near rivers or lakes. In Uganda, almost no transmission was found to have occurred at altitudes greater than 1400 m or where the annual rainfall was less than 900 mm.

In the Western Pacific Region, intestinal schistosomiasis, caused by Schistosoma japonicum is endemic in the Philippines and China and caused by Schistosoma mekongi is endemic in two provinces in Cambodia and one province in the Lao People's Democratic Republic. Intestinal schistosomiasis can cause abdominal pain, diarrhea, and blood in the stool. Elimination of schistosomiasis in the region is targeted through community empowerment with the One Health approach, composed of health promotion, preventive chemotherapy campaigns, improved water, sanitation and hygiene (WASH), treatment and management of domestic animals, and livestock, and focal snail control.

Competitive Landscape:

Some of the major players in the schistosomiasis treatment market include Chemos GmbH & Co. KG, Shin Poong Pharma. Co. Ltd., Meher Distributors Pvt. Ltd., Merck & Co., Salvensis, Bayer AG, LondonPharma Ltd, Merck & Co., Inc., 3S Corporation Kancera AB, Taj Pharmaceuticals Ltd., Avanscure Lifesciences Pvt. Ltd, CBC Pharma., VHB Life Science Inc., Samarth Pharma Pvt. Ltd., Taj Pharmaceuticals Ltd., and Egyptian International Pharmaceuticals Industries Co SAE (EIPICO). These companies offer various drugs, which are being used for preventive chemotherapy. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the schistosomiasis Drugs market globally.

In March 2019, IDDO launched a new global scientific collaboration dedicated to schistosomiasis and STHs with TDR (the Special Programme for Research and Training in Tropical Diseases). This aims to expand data re-use and collaboration and accelerate better treatment and control of these diseases, which affect more than a billion people globally.

In January 2020, Merck, a leading science and technology company, has donated 1 billion tablets of praziquantel, the standard medication for the treatment of schistosomiasis, to the World Health Organization (WHO). This marks a crucial milestone on the journey to the elimination of this neglected tropical disease (NTD) which mostly affects children in poor and rural communities. Since 2007, the company's praziquantel donations enabled the treatment of 400 million school-aged children in Sub-Saharan Africa.

Bayer AG

Overview:

Bayer AG is a German multinational pharmaceutical and life sciences company headquartered in Leverkusen. Bayer's areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals, seeds, and biotechnology products. The Pharmaceuticals Division focuses on prescription products, especially for women's healthcare and cardiology, and also on specialty therapeutics in the areas of oncology, hematology, and ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessary contrast agents.

Product Portfolio:

BILTRICIDE (praziquantel): Praziquantel is a medication used to treat a number of types of parasitic worm infections. Specifically, it is used for schistosomiasis, clonorchiasis, opisthorchiasis, tapeworm infections, cysticercosis, hydatid disease, and other fluke infections. It should not be used for worm infections of the eye. It is taken by mouth.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global schistosomiasis drugs market has seen negative growth from the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Site
  • 3.2. Market Snippet by Species Type
  • 3.3. Market Snippet by Drug Type
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising incidence of Schistosomiasis
    • 4.2.2. XX
  • 4.3. Restraints
    • 4.3.1. Stringent regulatory approvals
    • 4.3.2. XX
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Site

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site Segment
    • 7.1.2. Market Attractiveness Index, By Site Segment
  • 7.2. Intestinal Schistosomiasis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Urogenital schistosomiasis

8. By Species Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type Segment
    • 8.1.2. Market Attractiveness Index, By Species Type Segment
  • 8.2. Schistosoma mansoni*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Schistosoma japonicum
  • 8.4. Schistosoma mekongi
  • 8.5. Schistosoma guineensis
  • 8.6. Schistosoma haematobium

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 9.1.2. Market Attractiveness Index, By Drug Type Segment
  • 9.2. Praziquantel (Biltricide)*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3. Oxamniquine (Vansil)
  • 9.4. Metrifonate
  • 9.5. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies
  • 10.5. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Bayer AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Merck & Co., Inc.
  • 13.3. Avanscure Lifesciences Pvt. Ltd.
  • 13.4. Shin Poong Pharma.Co., Ltd.
  • 13.5. Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)
  • 13.6. CBC Pharma.
  • 13.7. Chemos GmbH & Co. KG.
  • 13.8. VHB Life Science Inc.
  • 13.9. 3S Corporation Kancera AB
  • 13.10. Taj Pharmaceuticals Ltd. (List Not Exhaustive)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us